230 related articles for article (PubMed ID: 29679103)
1. SLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipients.
Balke EM; Demeester S; Lee D; Gillard P; Hilbrands R; Van de Velde U; Van der Auwera BJ; Ling Z; Roep BO; Pipeleers DG; Keymeulen B; Gorus FK
Diabetologia; 2018 Jul; 61(7):1623-1632. PubMed ID: 29679103
[TBL] [Abstract][Full Text] [Related]
2. HLA-A*24 Carrier Status and Autoantibody Surges Posttransplantation Associate With Poor Functional Outcome in Recipients of an Islet Allograft.
Demeester S; Balke EM; Van der Auwera BJ; Gillard P; Hilbrands R; Lee D; Van de Velde U; Ling Z; Roep BO; Pipeleers DG; Gorus FK; Keymeulen B
Diabetes Care; 2016 Jun; 39(6):1060-4. PubMed ID: 27208324
[TBL] [Abstract][Full Text] [Related]
3. Use of Culture to Reach Metabolically Adequate Beta-cell Dose by Combining Donor Islet Cell Isolates for Transplantation in Type 1 Diabetes Patients.
Lee D; Gillard P; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Keymeulen B
Transplantation; 2020 Oct; 104(10):e295-e302. PubMed ID: 32433237
[TBL] [Abstract][Full Text] [Related]
4. Primary graft function, metabolic control, and graft survival after islet transplantation.
Vantyghem MC; Kerr-Conte J; Arnalsteen L; Sergent G; Defrance F; Gmyr V; Declerck N; Raverdy V; Vandewalle B; Pigny P; Noel C; Pattou F
Diabetes Care; 2009 Aug; 32(8):1473-8. PubMed ID: 19638525
[TBL] [Abstract][Full Text] [Related]
5. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft.
Keymeulen B; Ling Z; Gorus FK; Delvaux G; Bouwens L; Grupping A; Hendrieckx C; Pipeleers-Marichal M; Van Schravendijk C; Salmela K; Pipeleers DG
Diabetologia; 1998 Apr; 41(4):452-9. PubMed ID: 9562350
[TBL] [Abstract][Full Text] [Related]
6. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients.
Kang ES; Kim MS; Kim YS; Kim CH; Han SJ; Chun SW; Hur KY; Nam CM; Ahn CW; Cha BS; Kim SI; Lee HC
Diabetes; 2008 Apr; 57(4):1043-7. PubMed ID: 18162509
[TBL] [Abstract][Full Text] [Related]
7. Immediate Postoperative Insulin Requirements May Predict Metabolic Outcome after Total Pancreatectomy and Islet Autotransplantation.
Verma N; Rajab A; Buss J; Lara L; Porter K; Hart P; Conwell D; Washburn WK; Black S; Kuntz K; Meng S
J Diabetes Res; 2020; 2020():9282310. PubMed ID: 33426086
[TBL] [Abstract][Full Text] [Related]
8. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
Warnock GL; Meloche RM; Thompson D; Shapiro RJ; Fung M; Ao Z; Ho S; He Z; Dai LJ; Young L; Blackburn L; Kozak S; Kim PT; Al-Adra D; Johnson JD; Liao YH; Elliott T; Verchere CB
Arch Surg; 2005 Aug; 140(8):735-44. PubMed ID: 16103282
[TBL] [Abstract][Full Text] [Related]
9. Beta Cell Death by Cell-free DNA and Outcome After Clinical Islet Transplantation.
Gala-Lopez BL; Neiman D; Kin T; O'Gorman D; Pepper AR; Malcolm AJ; Pianzin S; Senior PA; Campbell P; Glaser B; Dor Y; Shemer R; Shapiro AMJ
Transplantation; 2018 Jun; 102(6):978-985. PubMed ID: 29329189
[TBL] [Abstract][Full Text] [Related]
10. Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity.
Rickels MR; Kamoun M; Kearns J; Markmann JF; Naji A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2410-4. PubMed ID: 17488791
[TBL] [Abstract][Full Text] [Related]
11. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft.
Keymeulen B; Gillard P; Mathieu C; Movahedi B; Maleux G; Delvaux G; Ysebaert D; Roep B; Vandemeulebroucke E; Marichal M; In 't Veld P; Bogdani M; Hendrieckx C; Gorus F; Ling Z; van Rood J; Pipeleers D
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17444-9. PubMed ID: 17090674
[TBL] [Abstract][Full Text] [Related]
12. Five-year follow-up after clinical islet transplantation.
Ryan EA; Paty BW; Senior PA; Bigam D; Alfadhli E; Kneteman NM; Lakey JR; Shapiro AM
Diabetes; 2005 Jul; 54(7):2060-9. PubMed ID: 15983207
[TBL] [Abstract][Full Text] [Related]
13. Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients.
Hirsch D; Odorico J; Danobeitia JS; Alejandro R; Rickels MR; Hanson M; Radke N; Baidal D; Hullett D; Naji A; Ricordi C; Kaufman D; Fernandez L
Am J Transplant; 2012 May; 12(5):1275-89. PubMed ID: 22300172
[TBL] [Abstract][Full Text] [Related]
14. Impact of the number of infusions on 2-year results of islet-after-kidney transplantation in the GRAGIL network.
Borot S; Niclauss N; Wojtusciszyn A; Brault C; Demuylder-Mischler S; Müller Y; Giovannoni L; Parnaud G; Meier R; Badet L; Bayle F; Frimat L; Kessler L; Morelon E; Penfornis A; Thivolet C; Toso C; Morel P; Bosco D; Colin C; Benhamou PY; Berney T;
Transplantation; 2011 Nov; 92(9):1031-8. PubMed ID: 21926944
[TBL] [Abstract][Full Text] [Related]
15. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial.
Lablanche S; Vantyghem MC; Kessler L; Wojtusciszyn A; Borot S; Thivolet C; Girerd S; Bosco D; Bosson JL; Colin C; Tetaz R; Logerot S; Kerr-Conte J; Renard E; Penfornis A; Morelon E; Buron F; Skaare K; Grguric G; Camillo-Brault C; Egelhofer H; Benomar K; Badet L; Berney T; Pattou F; Benhamou PY;
Lancet Diabetes Endocrinol; 2018 Jul; 6(7):527-537. PubMed ID: 29776895
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft.
Liu EH; Digon BJ; Hirshberg B; Chang R; Wood BJ; Neeman Z; Kam A; Wesley RA; Polly SM; Hofmann RM; Rother KI; Harlan DM
Diabetologia; 2009 Jul; 52(7):1369-80. PubMed ID: 19418039
[TBL] [Abstract][Full Text] [Related]
17. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression.
Lee D; Keymeulen B; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Gillard P
Transplantation; 2017 Sep; 101(9):2218-2227. PubMed ID: 27779572
[TBL] [Abstract][Full Text] [Related]
18. Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial.
Badet L; Benhamou PY; Wojtusciszyn A; Baertschiger R; Milliat-Guittard L; Kessler L; Penfornis A; Thivolet C; Renard E; Bosco D; Morel P; Morelon E; Bayle F; Colin C; Berney T;
Transplantation; 2007 Jul; 84(1):89-96. PubMed ID: 17627243
[TBL] [Abstract][Full Text] [Related]
19. Early metabolic markers of islet allograft dysfunction.
Baidal DA; Faradji RN; Messinger S; Froud T; Monroy K; Ricordi C; Alejandro R
Transplantation; 2009 Mar; 87(5):689-97. PubMed ID: 19295313
[TBL] [Abstract][Full Text] [Related]
20. Successful [correction of Succesful] transplantation of human islets in recipients bearing a kidney graft.
Bertuzzi F; Grohovaz F; Maffi P; Caumo A; Aldrighetti L; Nano R; Hengster P; Calori G; Di Carlo V; Bonifacio E; Secchi A
Diabetologia; 2002 Jan; 45(1):77-84. PubMed ID: 11845226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
